Inflammatory Bowel Diseases Clinical Trial
Under normal conditions intestinal mucosa presents a baseline "physiological inflammation"
caused by a controlled immune response that eliminates offending dietary and microbial
antigens. This inflammation disappears once the cause is eradicated. In case of
inappropriate immunological response, the inflammation becomes chronic and harmful,
resulting in anatomical and functional abnormalities, namely inflammatory bowel disease
(IBD).
Although it is critical for the IBD patients to undergo early diagnosis and management
before the development of severe complications, but as IBD has vague and non-pathognomonic
clinical features, the clinician is usually mislead into late suspicion and detection of
IBD.
Diagnosis traditionally depended on a combination of pathologic evaluation together with the
histological, clinical, radiological, endoscopic, surgical, laboratory (serological)
features. Recently, serological markers were identified and became of special interest as
they do not only detect the occurrence of IBD but also the potential of its development and
may be used as prognostic tools. More recently, stool markers were detected and used for
diagnosis.
Up to now, the market is still lacking a definitive, simple and non-invasive diagnostic
tool. Saliva can present an alternative form of body fluids that simplify diagnostic
procedures.
Our hypothesis is that IBD patients have special salivary biomarkers that may be identified
through salivary analysis, where later on a simple non-invasive test can be applied in the
form of an easy-to-use kit, being available at the clinician's clinic for the establishment
of an immediate and early diagnosis of the destructive inflammatory bowel disease.
n/a
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
| Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
| Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
| Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
| Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
| Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
| Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
| Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
| Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
| Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
| Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
| Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
| Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
| Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
| Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
| Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
| Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
| Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
| Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
| Completed |
NCT02874365 -
Intestinal Stem Cells Characterization
|
N/A |